| Name | c-Fms-IN-12 |
|---|---|
| Synonyms |
RY 382,RY
Imidazo[1,2-a]pyridine-3-cboxamide, N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-indazol-4-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy] RY382 RRY-382 N-(3-cyclopropyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)imidazo[1,2-a]pyridine-3-cboxamide RY-382 |
| Description | c-Fms-IN-12 is a c-Fms inhibitor extracted from patent WO2011079076A1, Compound Example 65, has an IC50 of 93.6-283.7 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
c-Fms[1] |
| In Vitro | cFMS, a type III receptor tyrosine kinases, which are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain[1]. |
| References |
| Molecular Formula | C32H36N8O2 |
|---|---|
| Molecular Weight | 564.68 |